CUVITRU is a ready-to-use liquid medicine that is given under the skin (subcutaneously) to treat primary immunodeficiency (PI) in people 2 years and older.
CUVITRU [Immune Globulin Subcutaneous (Human)] 20% is approved for the treatment of PI in people 2 years and older. When your child is diagnosed with PI, there are questions, worries, and uncertainties. Understanding your child’s PI and managing it with treatment that can be tailored to meet your child’s individual infusion needs can make a difference.1,2
We’ve created a brochure for caregivers about PI and its treatment with CUVITRU. It’s packed full of helpful information designed to boost your confidence about helping your child with treatment.
Doctor Discussion Guide
Talk to your child’s doctor to see if CUVITRU is right for them. We have a Doctor Discussion Guide that you can fill out for your child to answer questions about infusion concerns and preferences that might be a helpful starting place for a conversation.
*Results represent an example patient experience. Individual results may vary.
They may feel like the child with PI is receiving all the attention, so getting them involved could help avoid hurt feelings.
1. CUVITRU. Prescribing Information, Takeda Pharmaceuticals USA Inc.; 2023.
2. Data on file. Takeda US Inc. 2015.